Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASRTNASDAQ:IMRXNASDAQ:PGENNASDAQ:VRCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$0.63-4.5%$0.65$0.51▼$1.80$63.13M0.29650,876 shs432,219 shsIMRXImmuneering$2.56-7.6%$1.62$1.00▼$3.83$99.68M0.012.51 million shs4.70 million shsPGENPrecigen$1.45-2.7%$1.43$0.65▼$2.17$439.82M1.841.37 million shs2.11 million shsVRCAVerrica Pharmaceuticals$0.58+1.0%$0.54$0.38▼$8.98$53.53M1.75589,447 shs368,610 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio0.00%+6.84%-3.94%-8.46%-40.08%IMRXImmuneering0.00%+41.33%+76.43%+53.89%+87.16%PGENPrecigen0.00%-1.97%+5.67%-17.68%-5.10%VRCAVerrica Pharmaceuticals0.00%-14.10%-10.00%+3.73%-92.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASRTAssertio1.653 of 5 stars3.51.00.00.00.60.81.3IMRXImmuneering3.3121 of 5 stars3.32.00.00.03.15.00.6PGENPrecigen3.9694 of 5 stars3.51.00.04.72.61.70.6VRCAVerrica Pharmaceuticals4.3348 of 5 stars3.13.00.04.73.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASRTAssertio 3.00Buy$2.75337.06% UpsideIMRXImmuneering 2.60Moderate Buy$13.25417.58% UpsidePGENPrecigen 3.00Buy$6.00313.79% UpsideVRCAVerrica Pharmaceuticals 2.20Hold$8.001,267.99% UpsideCurrent Analyst Ratings BreakdownLatest VRCA, IMRX, ASRT, and PGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025IMRXImmuneeringMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.006/18/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/18/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/12/2025PGENPrecigenJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.006/5/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/19/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.505/15/2025PGENPrecigenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/14/2025VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/13/2025ASRTAssertioAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/7/2025IMRXImmuneeringOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $21.005/6/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASRTAssertio$124.96M0.48$0.05 per share13.43$1.27 per share0.50IMRXImmuneering$320K287.92N/AN/A$1.33 per share1.92PGENPrecigen$3.92M109.19N/AN/A$0.13 per share11.15VRCAVerrica Pharmaceuticals$7.57M7.15N/AN/A($0.11) per share-5.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASRTAssertio-$21.58M-$0.32N/A20.97N/A-25.72%-24.87%-10.87%8/6/2025 (Estimated)IMRXImmuneering-$61.04M-$1.96N/AN/AN/AN/A-119.22%-99.22%8/5/2025 (Estimated)PGENPrecigen-$126.24M-$0.56N/AN/AN/A-3,728.87%-279.20%-79.74%8/13/2025 (Estimated)VRCAVerrica Pharmaceuticals-$76.58M-$1.20N/AN/AN/AN/AN/A-145.63%8/13/2025 (Estimated)Latest VRCA, IMRX, ASRT, and PGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PGENPrecigen-$0.08-$0.07+$0.01-$0.18$0.50 million$1.34 million5/13/2025Q1 2025VRCAVerrica Pharmaceuticals-$0.14-$0.10+$0.04-$0.10$2.53 million$3.44 million5/12/2025Q1 2025ASRTAssertio-$0.06-$0.14-$0.08-$0.14$27.52 million$26.49 million5/5/2025Q1 2025IMRXImmuneering-$0.41-$0.42-$0.01-$0.42N/AN/A3/20/2025Q4 2024IMRXImmuneering-$0.42-$0.58-$0.16-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASRTAssertioN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASRTAssertio0.361.661.35IMRXImmuneeringN/A7.487.48PGENPrecigenN/A3.533.53VRCAVerrica PharmaceuticalsN/A1.341.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASRTAssertio48.96%IMRXImmuneering67.65%PGENPrecigen33.51%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipASRTAssertio4.00%IMRXImmuneering22.90%PGENPrecigen47.10%VRCAVerrica Pharmaceuticals54.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASRTAssertio2095.78 million91.95 millionOptionableIMRXImmuneering6035.99 million27.75 millionNot OptionablePGENPrecigen190295.18 million156.15 millionOptionableVRCAVerrica Pharmaceuticals4092.49 million42.55 millionOptionableVRCA, IMRX, ASRT, and PGEN HeadlinesRecent News About These CompaniesVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest UpdateJune 19 at 2:22 AM | americanbankingnews.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $8.00 Consensus PT from AnalystsJune 19 at 1:29 AM | americanbankingnews.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Significant Decline in Short InterestJune 18 at 2:43 AM | marketbeat.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by BrokeragesJune 16, 2025 | marketbeat.comVerrica Pharmaceuticals (NASDAQ:VRCA) Shares Up 0% - Here's WhyJune 10, 2025 | marketbeat.comVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New YorkMay 28, 2025 | globenewswire.comWall Street Zen Upgrades Verrica Pharmaceuticals (NASDAQ:VRCA) to "Hold"May 24, 2025 | marketbeat.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by AnalystsMay 24, 2025 | marketbeat.comResearch Analysts Offer Predictions for VRCA Q2 EarningsMay 20, 2025 | marketbeat.comVerrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in PipelineMay 18, 2025 | msn.comVerrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference CallMay 13, 2025 | seekingalpha.comVerrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comVerrica Pharmaceuticals Reports Quarterly 2025 Financial ResultsMay 13, 2025 | globenewswire.com6VRCA : Earnings Outlook For Verrica PharmaceuticalsMay 13, 2025 | benzinga.comVerrica Pharmaceuticals to Host Q1 2025 Earnings Call and Corporate UpdateMay 11, 2025 | msn.comVerrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025May 7, 2025 | globenewswire.comVerrica Pharmaceuticals CEO to Present at Citizens Life Sciences ConferenceMay 4, 2025 | msn.comVerrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New YorkApril 30, 2025 | globenewswire.comWhy Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 5.94%April 10, 2025 | aaii.comVerrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTHApril 9, 2025 | msn.comIn face of U.S. stock market selloff, shares of West Chester firm are on the riseApril 8, 2025 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVRCA, IMRX, ASRT, and PGEN Company DescriptionsAssertio NASDAQ:ASRT$0.63 -0.03 (-4.54%) Closing price 04:00 PM EasternExtended Trading$0.66 +0.03 (+5.37%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Immuneering NASDAQ:IMRX$2.56 -0.21 (-7.58%) Closing price 04:00 PM EasternExtended Trading$2.49 -0.07 (-2.77%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Precigen NASDAQ:PGEN$1.45 -0.04 (-2.68%) Closing price 04:00 PM EasternExtended Trading$1.45 0.00 (0.00%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Verrica Pharmaceuticals NASDAQ:VRCA$0.58 +0.01 (+1.04%) Closing price 04:00 PM EasternExtended Trading$0.58 +0.00 (+0.03%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
